Daewoong Pharmaceutical invests heavily in smart production infrastructure, "using it as a foundation for the National Growth Fund"

Lee Eok-won, chairman of the Financial Supervisory Service, visits Daewoo Smart Factory

10,000,000 infrastructure and 15% R&D capabilities combined

On the 13th, Daewoo Pharmaceutical announced that it held a meeting where officials from the Financial Supervisory Service, including Chairman Lee Eok-won, and other key financial sector figures visited Daewoo Pharmaceutical's smart factory in Osong, Chungcheongbuk-do, to confirm the core competitiveness of South Korea's pharmaceutical and biotechnology industry, and discussed the role of policy finance in enhancing industrial competitiveness.

This visit was arranged to seek practical measures for the "National Growth Fund" being promoted by the government to promote innovation in the pharmaceutical and biotechnology industries. Attendees included financial sector leaders such as Lee Eok-won, Chairman of the Financial Supervisory Service, Park Sang-jin, Chairman of Korea Development Bank, and Jang Min-young, President of IBK Industrial Bank, as well as related personnel such as Yoon Jae-chun, CEO of Daewoo Pharmaceutical, and Park Sung-soo, CEO of Daewoo Pharm.

CEO Yoon Jae-chun expressed deep trust in the policy direction being promoted by the Financial Supervisory Service. Yoon said, "The National Growth Fund is an essential catalyst for advanced industries such as pharmaceuticals and biotechnology, which require long-term commitment and large-scale investment," adding, "This will be an important milestone in completing the nation's ambitious goal of becoming a global leader in pharmaceuticals and biotechnology."

On that day, Park Sung-soo, CEO of Daewon Pharmaceutical, presented plans to create synergies with government policies based on the company's globally top-tier competitiveness that has been built up. Park said, "Daewon Pharmaceutical has already invested a cumulative 1 trillion won in production infrastructure targeting the global market through independent investments, and last year also made a 220 billion won R&D investment, showing sincere efforts to become a global pharmaceutical company," and added, "If additional policy support from the government, such as the National Growth Fund, is provided, it will significantly shorten the time required to secure a competitive advantage in the global market."

The government's National Growth Fund is a mega project with a total investment of 150 trillion won through a joint effort between the public and private sectors. It is evaluated as a key financial infrastructure for the economic revival of South Korea, aiming to secure national growth momentum and enhance global competitiveness through the development of advanced strategic industries.

On this day, the visiting delegation inspected the Osong Smart Factory, which is a key hub where Daewoong Pharmaceutical's advanced manufacturing process technology is concentrated, characterized as a "factory that cannot be manipulated." While all pharmaceutical factories are operated according to GMP (Good Manufacturing Practice), Daewoong Pharmaceutical has gone one step further by completing processes that do not allow human intervention.

There may be attempts to correct data when minor errors occur in the manufacturing process, but Daewoong Pharmaceutical's smart factory is structured to automatically generate and store all process records in real time. In particular, if there is even a 0.01% deviation from quality standards, the system immediately halts the next process, thereby completely eliminating any opportunity for manual intervention.

Daewoo Pharmaceutical emphasized that this process ultimately prevents defects from the source, thereby establishing a unique "quality competitiveness." Daewoo Pharmaceutical's quality competitiveness meets the data integrity standards strictly required by global regulatory agencies such as the U.S. FDA and the European EMA.

Daewoo Pharmaceutical is also focusing on enhancing its R&D competitiveness, in addition to infrastructure. It reinvests 15% of its annual sales into research and development. Alongside this, it is exploring an innovative, full-cycle model that incorporates digital healthcare technologies for prevention, diagnosis, and management, presenting a vision for the future of the healthcare industry beyond traditional pharmaceutical manufacturing.

Lee Eok-won, chairman of the Financial Supervisory Service, who visited Daewoo Pharmaceutical's Osong Smart Factory, said, "The potential of South Korea's pharmaceutical and biotech industries, as confirmed at the advanced smart factory site, is very encouraging." He added, "The National Growth Fund will not hesitate to provide policy support to enable bold investments by innovative companies, leading to tangible achievements in the global market."

Live popular news articles

1st place"Crash" Season 2 to air in second half of the year... Lee Min-ki, Kwon Sun-young, etc., make appearance
2nd placePark Ji-hoon's 'The Legend of the Soldier', Inviting French Series Fans
3rd placeCJ Logistics, Gmarket's 'Star Delivery X One' Joint Promotion Event